Feb. 13, 2007 — Locus Pharmaceuticals Inc., a computationally based drug design and development company, announced today that it has closed on a $30.2 million financing. Novartis Bioventures Ltd., Prism Venture Partners and HBM BioVentures (Cayman) Ltd. co-led the round. S.R. One Limited and L Capital Partners SBIC L.P. also participated, as did certain other existing shareholders of the Company.
Locus Pharmaceuticals is focused on developing novel, small molecule therapeutic drugs to address major unmet medical needs. It has effectively integrated its core technology with the application of chemistry and biology expertise to advance three internal programs that address new therapeutic modalities for the treatment of HIV/AIDS, cancer and arthritis/inflammation.